v3.26.3
Consolidated Income Statements - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Revenue $ 2,201 $ 2,268 $ 6,662 $ 6,638
Cost of revenue 1,294 1,385 3,989 4,095
Gross profit 907 883 2,673 2,543
Selling, general and administrative expenses 458 474 1,433 1,437
Research and development expenses 56 52 171 166
Restructuring and asset impairment charges 8 23 50 70
Operating income 385 334 1,019 870
Interest expense (21) (6) (32) (23)
Other non-operating income, net 6 6 3 13
Loss on sale of businesses (5) (37) (17) (47)
Income before income taxes 365 297 973 813
Income tax expense (77) (71) (235) (196)
Net income 288 226 738 617
Net loss attributable to non-controlling interests 3 1 9 5
Net income attributable to Xylem $ 291 $ 227 $ 747 $ 622
Earnings per share:        
Basic (in dollars per share) $ 1.25 $ 0.93 $ 3.15 $ 2.56
Diluted (in dollars per share) $ 1.25 $ 0.93 $ 3.14 $ 2.55
Basic (in shares) 232,719 243,454 237,262 243,319
Diluted (in shares) 233,040 244,091 237,658 243,910
Product        
Revenue $ 1,807 $ 1,867 $ 5,517 $ 5,487
Cost of revenue 1,026 1,109 3,176 3,279
Service        
Revenue 394 401 1,145 1,151
Cost of revenue $ 268 $ 276 $ 813 $ 816